Tech Company Financing Transactions
Santhera Pharmaceuticals AG Funding Round
On 12/17/2004, Santhera Pharmaceuticals AG raised $18 million in Series A funding from NGN Capital.
Transaction Overview
Company Name
Announced On
12/17/2004
Transaction Type
Venture Equity
Amount
$17,961,800
Round
Series A
Investors
NGN Capital (Lead Investor) (Georg Nebgen)
Proceeds Purpose
The capital raised in this round will allow us to advance the clinical and preclinical development of our novel therapies in the areas of neuromuscular and metabolic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Hohenrainstrasse 24
Pratteln, 4133
Switzerland
Pratteln, 4133
Switzerland
Phone
Website
Email Address
Overview
The company is focused on the discovery, preclinical as well as clinical Santhera Pharmaceuticals is a Swiss biopharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Elmar Schnee
Chief Executive Officer
Thomas Meier
Chief Financial Officer
Christoph Rentsch
Chief Medical Officer
Kristina Nygren
VP - Bus. Development
Günther Metz
VP - General Counsel
Oliver Strub
Browse more venture capital transactions:
Prev: 12/16/2004: Splunk venture capital transaction
Next: 12/20/2004: BiPar Sciences venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs